LY500307 is a potent and selective nonsteroidal estrogen receptor beta (ERβ) agonist. It is a synthetic small molecule with high binding affinity and functional selectivity for ERβ over ERα, making it a valuable pharmacological tool and a candidate therapeutic agent. Its primary application is in research and development for treating central nervous system (CNS) disorders and metabolic conditions. Preclinical studies have investigated its potential in models of schizophrenia, cognitive impairment, depression, and anxiety, leveraging ERβ's role in neuroprotection and neuroinflammation modulation. It has also been explored for potential benefits in metabolic syndrome and obesity. As a selective ERβ agonist, LY500307 represents a class of compounds aimed at achieving the beneficial effects of estrogen signaling, such as neuroprotection and metabolic regulation, while minimizing the risks associated with ERα activation, like carcinogenesis in reproductive tissues. Its development highlights the therapeutic targeting of specific estrogen receptor subtypes.